A Study About Remote and Local Liver Surgery

Summary

The goal of this clinical trial is to learn if the robotic surgical system producted by Shenzhen Edge Medical Company has a non-inferior textbook outcome in liver surgery in the field of remote surgery compared to local robotic surgery. It will also learn about the safety of remote liver surgery.

The main questions are: Does remote liver surgery not lower the textbook outcomes in liver surgery compared to the local robotic surgery? What complications do participants have when taking remote liver surgery? Investigators will compare remote liver surgery to local robotic liver surgery to see if remote liver surgery doesn't lower the textbook outcome in liver surgery.

Participants will:

Undergo remote or local robotic liver surgery according to the random program; Visit the clinic in 3, 28 and 42 day after surgery for checkups and tests; Keep a diary of their postoperative complications.

Conditions

• Liver Diseases

Interventions

DEVICE

Remote Liver Surgery

The patients in this arm will undergo remote liver surgery.

DEVICE

Local Liver Surgery

The patients in this arm will undergo local liver surgery.

Sponsors & Collaborators

• The First Medical Center of Chinese PLA General Hospital

  collaborator OTHER

• The First Affiliated Hospital of Anhui Medical University

  collaborator OTHER

• First Affiliated Hospital of Guangxi Medical University

  collaborator OTHER

• The Affiliated Hospital Of Guizhou Medical University

  collaborator OTHER

• Affiliated Hospital of Qinghai University

  collaborator OTHER

• First Affiliated Hospital of Harbin Medical University

  collaborator OTHER

• Xinqiao Hospital, Amry Medical University

  collaborator UNKNOWN

• Wuhan TongJi Hospital

  collaborator OTHER

• Zhujiang Hospital

  collaborator OTHER

• The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

  collaborator OTHER

• First Affiliated Hospital of Chengdu Medical College

  collaborator OTHER

• Tongji Hospital

  lead OTHER

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Model

FACTORIAL

Eligibility

Min Age

18 Years

Max Age

75 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2026-05-16

Primary Completion

2027-12-31

Completion

2028-07-31

Countries

• China

Study Locations